2,6-Dimethyl-trans,trans-2,6-nonadien-1-ol | 33835-57-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2,6-Dimethyl-trans,trans-2,6-nonadien-1-ol
• 英文别名: (2E,6E)-2,6-dimethyl-nona-2,6-dien-1-ol；(2E,6E)-2,6-dimethylnona-2,6-dien-1-ol
• CAS: 33835-57-3
• 化学式: C₁₁H₂₀O
• 分子量: 168.279
• InChiKey: WFCPGJYWGLLKKN-NSJFVGFPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-Iodo-6-methyl-8-(2'-tetrahydropyranyloxy)-trans,trans-octadien-1-ol 、 甲基锂 生成 2,6-Dimethyl-trans,trans-2,6-nonadien-1-ol
  参考文献：
  名称：

  Novel cyclization mediated by organocopper reagents

  摘要：

  DOI：

  10.1021/jo00974a034

文献信息

• PROCESS FOR THE PREPARATION OF VITAMIN K2
  申请人：Skattebol Lars

  公开号：US20110207967A1

  公开（公告）日：2011-08-25

  Using a combination of Kumada, Suzuki and Biellmann chemistry, various menaquinones can synthesised rapidly and with stereochemical integrity offering a new way of preparing these vitamin K2 components for the pharmaceutical market. In one embodiment a process for the preparation of a compound of formula (I) is defined including a step in which (i) a compound of formula (II) is reacted formula (III) wherein R is an alkyl group; LG is a leaving group; m is an integer from 0 to 8; n is an integer of from 0 to 9; and X is hydrogen, halide, hydroxyl or protected hydroxyl; in the presence of a copper, nickel or palladium catalyst.

  通过 Kumada、Suzuki 和 Biellmann 化学反应的组合，可以快速合成各种维生素K2成分的甲萘醌，具有立体化学完整性，为制备这些成分进入药品市场提供了新的途径。在一种实施例中，定义了一种制备公式（I）化合物的过程，其中包括以下步骤：（i）在铜、镍或钯催化剂的存在下，将公式（II）化合物和公式（III）化合物反应，其中 R 是烷基；LG 是离去基团；m 是从0到8的整数；n 是从0到9的整数；X 是氢、卤素、羟基或保护羟基。
• Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient
  申请人：Saimoto Hiroyuki

  公开号：US20130296422A1

  公开（公告）日：2013-11-07

  Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I) (wherein, X represents a hydrogen atom or a halogen atom; R 1 represents a hydrogen atom; R 2 represents a hydrogen atom or a C 1-7 alkyl group; R 3 represents —CHO, —C(═O)R 5 , —COOR 5 (wherein R 5 represents a C 1-7 alkyl group), —CH 2 OH or —COOH; and R 4 represents a C 1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C 2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C 2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s)), an optical isomer thereof, and a pharmaceutically acceptable salt is used.

  以下新化合物对于预防或治疗由原虫引起的疾病是有用的。其中至少一种由公式（I）表示的化合物（其中，X表示氢原子或卤素原子；R1表示氢原子；R2表示氢原子或C1-7烷基；R3表示—CHO，—C（═O）R5，—COOR5（其中R5表示C1-7烷基），—CH2OH或—COOH；R4表示具有一个或多个取代基的C1-16烷基，在末端碳原子和/或非末端碳原子上，具有一个或多个取代基的C2-16烯基，或者具有一个或多个取代基的C2-16炔基），其光学异构体和药学上可接受的盐被使用。
• DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR
  申请人：NAI INC.

  公开号：US20150166498A1

  公开（公告）日：2015-06-18

  The present invention provides a novel dihydroorotic acid dehydrogenase inhibitor which is applicable to various diseases. When used as an active ingredient, a compound represented by formula (I): (wherein X represents a halogen atom, R 1 represents a hydrogen atom, R 2 represents an alkyl group containing 1 to 7 carbon atoms, R 3 represents —CHO, and R 4 represents —CH 2 —CH═C(CH 3 )—R 0 (wherein R 0 represents an alkyl group containing 1 to 12 carbon atoms which may have a substituent on the terminal carbon and/or on a non-terminal carbon, etc.)), an optical isomer thereof or a pharmaceutically acceptable salt thereof has a high inhibitory effect on dihydroorotic acid dehydrogenase and can be used as an immunosuppressive agent, a therapeutic agent for rheumatism, an anticancer agent, a therapeutic agent for graft rejection, an antiviral agent, an anti- H. pylori agent, a therapeutic agent for diabetes or the like.

  本发明提供了一种新型的二氢乳酸酸脱氢酶抑制剂，可用于多种疾病。当用作活性成分时，式（I）所表示的化合物：（其中X表示卤素原子，R1表示氢原子，R2表示含有1至7个碳原子的烷基，R3表示—CHO，R4表示—CH2—CH═C(CH3)—R0（其中R0表示含有1至12个碳原子的烷基，其末端碳和/或非末端碳上可能有取代基等），其光学异构体或其药学上可接受的盐对二氢乳酸酸脱氢酶具有高抑制作用，可用作免疫抑制剂、治疗风湿病的药物、抗癌药物、移植排斥治疗药物、抗病毒药物、抗H. pylori药物、糖尿病治疗药物或类似药物。
• Lipo-Conjugation of Peptides
  申请人：DeFrees Shawn

  公开号：US20090054623A1

  公开（公告）日：2009-02-26

  The present invention provides peptide conjugates that are formed between a modified lipid and a glycosyl residue and/or an amino acid residue on a peptide. The modified lipid includes a modifying group and a lipid linking group. Exemplary lipid linking groups include myristoyl, palmitoyl, and isoprenyl moieties.
• Enzymatic modification of glycopeptides
  申请人：Defrees Shawn

  公开号：US20090292110A1

  公开（公告）日：2009-11-26

  The present invention provides glycoconjugates that are formed through the enzymatically-mediated coupling of a glycosyl moiety, e.g., on a peptide or lipid, and a modifying group that includes an acyl group. The conjugates include the modifying group tethered to the glycosyl moiety through a linking moiety that includes an acyl residue. Also provided are methods for preparing the conjugates of the invention